Role progress of mitochondrial coupling factor 6 in pulmonary hypertension
10.3760/cma.j.issn.1008-6706.2020.10.031
- VernacularTitle:线粒体偶联因子6在肺动脉高压发生中的作用
- Author:
Juan ZHANG
1
;
Linlin ZHANG
;
Zhan ZHANG
;
Peishuang WANG
Author Information
1. 中国科技大学附属第一医院西区重症医学科，合肥 230003
- From:
Chinese Journal of Primary Medicine and Pharmacy
2020;27(10):1278-1280
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary hypertension (PAH) is a common pathological stats disease in clinic, it has a high morbidity and mortality.It was found that abnormal of endothelial growth factor, coagulation-related factors, 5-hydroxytryptamine, interleukin-6 and other inflammatory factors, hypoxia-inducible factors, transforming growth factor-β1 and connective tissue growth factor(CTGF) and so on were involved in the occurrence and development of PAH, but the specific mechanism was still unclear.In recent years, in monocrotaline(MCT) induced PAH rats model, they found that MCT rats had a significant higher concentration of mitochondrial coupling factor 6 (CF6) in both plasma and lung tissue than control group, which inhibited the activity of prostacyclin (PGI2), suggesting that CF6 may be involved in the occurrence and development of PAH.This paper will discuss the characteristics of CF6, the relationship between PGI2 and CF6, the relationship between PAH and CF6.
